Navigation Links
PFS in Medical News

Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

...udy also showed that patients treated with TREANDA had significantly longer pfs compared to chlorambucil (median pfs 21.6 months vs. 8.3 months; p<0.0001). TREANDA was also associated with...

New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud

... Accounts Management Handbook . He has also authored many articles which have appeared in various industry publications. He is also the creator of pfs Power Rankings(sm) , a national benchmarking system for hospital Patient Financial Services (PFS) departments. Mr. DeKaye's Emphasis on Education(...

Advanced targeted therapies effective as first-line treatment for lung cancer

...sis of the total patient population. Further, a pfs benefit was seen with erlotinib regardless of the ...he most common and deadly form of lung cancer, the pfs time that erlotinib can offer represents a signifi...whether vandetanib plus chemotherapy prolonged the pfs of advanced NSCLC patients when compared to chemot...

Electronic Forms Management Suite from Access Delivers Admissions Efficiency at Laughlin Memorial Hospital

...at was left was for Access consultants to deploy pfs and the supporting e-Forms Repository (EFR). ...ented a product that makes their lives easier, and pfs is a great complement to our Meditech Client Serve...e of human error." Now that she has seen pfs and EFR in action, Crouch believes that choosing ...

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

... primary platinum resistant disease, including 40 patients (53%) on the TELCYTA plus PLD arm and 35 patients (47%) on the PLD control arm. The median pfs of these patients was 5.6 months for the TELCYTA plus PLD arm compared to 2.9 months for the PLD control arm, p=0.0425 and HR=0.55. The response rate...

Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer

...ients. "The PSA response, disease control and pfs in this Phase 2 trial are encouraging and suggest ...ed and prednisone 5 mg alone.i The median pfs using PSA was 8.5 months for patients who received... to be encouraged by the Phase 2 proof-of-concept, pfs data and believe the efficacy findings thus far su...

Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say

...archers found an 82 percent progression-free survival in the group. The 39 high-risk patients had a 77 percent PFS, and, for the 39 low-risk patients, pfs was 88 percent. Patients are deemed high risk if they have three or more poor prognostic factors, such as age (60 years or older), elevated LDH (a blo...

Two targeted therapies likely better than one in patients with aggressive lymphoma

...archers found an 82 percent progression-free survival in the group. The 39 high-risk patients had a 77 percent PFS, and, for the 39 low-risk patients, pfs was 88 percent. Patients are deemed high risk if they have three or more poor prognostic factors, such as age (60 years or older), elevated LDH (a blo...

New universal breast cancer marker predicts recurrence and clinical outcome

...val (PFS) was also affected by the loss of stromal caveolin-1. Overall, the pfs in patients with an absence of stromal caveolin-1 was reduced by approximately 3.6-fold. In lymph-node positive patients, the difference in pfs was especially pronounced: The approximate five-year survival rate for pati...

Halo Pharmaceutical Completes $14.6 Million in Financing from The Provident Bank

...branches throughout northern and central New Jersey. The Provident Bank is the wholly owned subsidiary of Provident Financial Services, Inc. (NYSE: pfs ), which reported assets of $6.6 billion as of December 31, 2008. ...
PFS in Medical Technology

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... more than 90 percent of the 1,183 patients enrolled in the trial. Importantly, in patients with tumors harboring activating KRAS mutations, pfs was significantly inferior in the Vectibix arm. These data confirm previous findings when oxaliplatin-based chemotherapy and an anti-EGFR antibody are...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

...rexed did show a positive trend in prolongation of pfs compared with pemetrexed alone. ZEAL is a ran...rating a statistically significant prolongation of pfs for vandetanib was not met in this study, in a pre...as shown to have similar efficacy to erlotinib for pfs and OS (PFS: hazard ratio [HR] 0.98, 95.22% CI 0.8...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

...Stable Disease or Partial Response The median pfs for all 46 patients was 12.5 weeks [95% CI (11.9, ...olimus). For this group, best response and median pfs to single agent perifosine was as follows: ...OR and VEGF receptor inhibitor, which had a median pfs of 16 weeks. Given the manageable safety profile ...

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

...ave been enrolled and 28 patients were evaluable for efficacy. The 16-week pfs rate (for part 2) was 45 percent (95 percent CI, 26 percent to 62 percent); median pfs was 16 weeks (95 percent CI, 15 to 31 weeks). The complete response rate w...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

...is comparing the safety and efficacy (assessed by objective tumor response, pfs and overall survival) of intravenous picoplatin given once every four weeks...t the ASCO Annual Meeting, demonstrated that: The median pfs in the intent-to-treat population was 6.8 months for patients randomized an...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

...effect on the pre-specified secondary endpoints of pfs (p=0.023) and Categorical Change in FVC (p=0.001) when compared to placebo. A pfs event was defined in the study protocol as the tim... a treatment effect favoring pirfenidone on three: pfs (p=0.029); Categorical FVC Change (p=0.003) and Si...

Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial

...h relapsed aggressive NHL and these dramatic and significant differences in pfs in this tough to treat group of patients provides that evidence," stated Ja...gent in this patient population to demonstrate a significant and meaningful pfs advantage. We believe these data will support a priority review designation...

RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

...mary endpoint, 29 patients (55%) had stable disease, 22 (41%) had progressive disease and 2 (4%) had an unknown response. The ORR was zero. The median pfs was 83 days (95% Confidence Interval: 50 - 91 days), with 29.6% of patients estimated to still be progression-free at four months. Median overall surv...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

...percent among the total patient population. Median pfs time was 7.7 months, and median OS time was 19.1 m...tute (NCI) criteria, and researchers also assessed pfs and OS. Patients had a variety of cytogenetic abno...malities had an ORR of 27 percent. Median pfs and OS for the whole group were 6.9 months and 30 ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

...ich were presented by Professor Harousseau, showed: -- The two year pfs was 69 percent in the VcD arm, compared with 60 percent in the VAD a...stitute of Hematology and Medical Oncology, showed: -- The two-year pfs was 90 percent in the VcTD arm, compared with 80 percent in the TD arm (p=0...
PFS in Medical Products

Bledsoe Nite 'N Day Plantar Fasciitis Orthosis

Description:...h the Achilles tendon to provide relief and prevent future discomfort. For patients experiencing only mild to moderate PF pain, please see the Bledsoe pfs Plantar Fasciitis Support. Indications This device is indicated for day and night use in the treatment of moderate to severe plantar fasciitis as an ...
Company:Bledsoe Brace Systems

Cygnus-PFS() Image-Guided Surgery System

Features:... Cygnus pfs Image Guided System was the first portable frameless stereotaxy system for neurosurgical procedures. The latest software includes enhanced selection o...
Company:Compass International, Inc.
PFS in Biological News

Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer

...9 days, range: 1*-397 days), and the median overall survival (OS) rate was 10.3 months (315 days, range: 19-604 days; 95% CI: 279-350). The six-month pfs and OS rates were 16.0% (95% CI: 8.6-17.0) and 72.3%, respectively (95% CI: 66.9-77.6). The safety analysis included all 291 patients who received ...
PFS in Biological Technology

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

...Meeting. The results continue to support picoplatin as a neuropathy-sparing alternative to oxaliplatin with similar anti-tumor activity as assessed by pfs and disease control measured by tumor response rate. New data derived by three independent assessments indicated a statistically significant reductio...

Sunesis Reports Financial Results for the Second Quarter 2009

...ogression free survival (PFS) for each of the three cohorts by increasing dose is 82 days, 84 days, and 109 days, respectively. The preliminary median pfs for the 44 women who were both platinum resistant and also had failed treatment with Doxil(R) is 90 days. In July, Sunesis receive...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial

...currently six months, while the overall survival is currently seven months. The literature suggests that platinum refractory patients typically have a pfs of approximately two months and a median survival ranging from 4.5 to 6.5 months. The overall survival figure may evolve as many of the patients are s...

InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF

...effect on the pre-specified secondary endpoints of pfs (p = 0.023) and Categorical Change in FVC (p = 0.001) when compared to placebo. A pfs event was defined in the study protocol as the tim... a treatment effect favoring pirfenidone on three: pfs (p = 0.029); Categorical FVC Change (p = 0.003) an...

Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting

...nt on patients with wild-type KRAS tumors will avoid unnecessary adverse events in patients who are unlikely to benefit, maximize response rates and pfs in patients with wild-type KRAS genes, and redirect patients with a mutated KRAS gene to alternative therapies," said Sean Harper. "We are thrilled ...

Nikon Instruments Perfect Focus System Wins Second Place in The Scientist's Top Innovations of 2008 Award

...t in the past year, acknowledges Nikon's exclusive pfs system for its unique ability to provide real time...us drift caused by thermal and mechanical effects, pfs is a hardware component that helps address some of...d correct it for sampling every five milliseconds, pfs holds focus both in time-lapse experiments and in ...

Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer

...refractory or primary platinum resistant disease, including 40 patients on the Telcyta plus PLD arm and 35 patients on the PLD control arm. The median pfs of these patients was 5.6 months for the Telcyta plus PLD arm compared to 2.9 months for the PLD control arm, p = 0.0425 and HR = 0.55. The response r...

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

...ension formulation of tanespimycin. TIME-1 is designed with a primary endpoint of progression-free survival (PFS) and is designed to show a 2.75 month pfs benefit in patients treated with tanespimycin plus Velcade(R) (bortezomib) compared to patients treated with bortezomib alone. Kosan has completed b...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL

...Since progression-free survival (PFS) in this patient population historically approximates four months initial observations of nimotuzumab's effect on pfs could be available shortly after the response data." The single-arm trial in Canada is currently designed to enroll 100 patients in two 50-patient c...

Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer

...lone to 31.4% when Avastin was added -- Dose-reduction of IFN did not appear to affect the efficacy of the combination with Avastin (based on pfs event free rates over time, as shown by a sub-group analysis) The study also showed a trend towards improved overall survival; however, these dat...
Other Tags
(Date:7/10/2014)... Estonian-born Katerina Alba,s research at the University of Huddersfield ... the most popular emulsion-based food products such as ... is starting to gain an international profile for her ... and food science at the University and now she ... with her supervisor, Dr Vassilis Kontogiorgos, she is investigating ...
(Date:7/10/2014)... A neuroscientist at Rutgers University-Newark says the human brain ... a finding that could provide a better understanding ... conditions that afflict an estimated 13.6 million Americans. , ... , Michael Cole, an assistant professor at the Center ... brain architecture of a person at rest is basically ...
(Date:7/10/2014)... sarcomas research group at the Bellvitge Biomedical Research Institute ... been tested in 19 patients a new therapeutic combination ... indicate that the new treatment could stabilize the growth ... the British Journal of Cancer ., Sarcomas ... complex since there are several subtypes. It can affect ...
(Date:7/10/2014)... 10, 2014) Men who experience hot flashes are ... find relief from their silent suffering if they ... findings from a Baylor University case study., After seven ... had uncontrolled hot flashes following prostate cancer surgery showed ... also an impressive improvement in sleep quality, according to ...
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Low back pain? Don't blame the weather 2
(Date:7/10/2014)... business incubator, received a $1.4 million federal grant to ... staunch bleeding during brain surgery. , Surgeons can spray ... bio-polymer solutions in the gel will cohere and control ... The gel can shorten an intracranial surgery by 30- ... the patient,s skull to be open and less anesthesia, ...
(Date:7/10/2014)... State University have developed a small, portable and ... over the world better understand the radiation around them, ... poses a health risk. , The device was developed ... incident in Fukushima, Japan, in 2011, when many regional ... being exposed to and whether their homes, food, environment ...
(Date:7/10/2014)... Cancer Research Centre (CNIO) Macromolecular Crystallography Group has ... called BuD to DNA in order to redirect ... researcher who led the study, says the discovery: ... instructions contained in the genome to treat genetic ... is published in the journal Acta Crystallographica, ...
Breaking Biology News(10 mins):A start-up at NJIT develops bleeding-control gel for brain surgery 2Sophisticated radiation detector designed for broad public use 2Sophisticated radiation detector designed for broad public use 3CNIO scientists develop technology to redirect proteins towards specific areas of the genome 2
Other Contents